These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32956600)

  • 21. Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection.
    Li C; Hall TG; Hall JJ; He WQ
    Epidemiol Infect; 2023 Feb; 151():e37. PubMed ID: 36789960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
    Donken R; King AJ; Bogaards JA; Woestenberg PJ; Meijer CJLM; de Melker HE
    J Infect Dis; 2018 Apr; 217(10):1579-1589. PubMed ID: 29409034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
    Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
    J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling.
    Deleré Y; Remschmidt C; Leuschner J; Schuster M; Fesenfeld M; Schneider A; Wichmann O; Kaufmann AM
    BMC Infect Dis; 2014 Feb; 14():87. PubMed ID: 24552260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
    Guo F; Hirth JM; Berenson AB
    Hum Vaccin Immunother; 2015; 11(10):2337-44. PubMed ID: 26376014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
    Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
    Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of high-risk human papillomavirus after HPV-vaccination in Denmark.
    Lynge E; Thamsborg L; Larsen LG; Christensen J; Johansen T; Hariri J; Christiansen S; Rygaard C; Andersen B
    Int J Cancer; 2020 Dec; 147(12):3446-3452. PubMed ID: 32542644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway.
    Feiring B; Laake I; Christiansen IK; Hansen M; Stålcrantz J; Ambur OH; Magnus P; Jonassen CM; Trogstad L
    J Infect Dis; 2018 Nov; 218(12):1900-1910. PubMed ID: 30010913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
    Checchi M; Mesher D; Panwar K; Anderson A; Beddows S; Soldan K
    Vaccine; 2023 Oct; 41(45):6734-6744. PubMed ID: 37821315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An observational study comparing HPV prevalence and type distribution between HPV-vaccinated and -unvaccinated girls after introduction of school-based HPV vaccination in Norway.
    Enerly E; Flingtorp R; Christiansen IK; Campbell S; Hansen M; Myklebust TÅ; Weiderpass E; Nygård M
    PLoS One; 2019; 14(10):e0223612. PubMed ID: 31600341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.
    Kahn JA; Widdice LE; Ding L; Huang B; Brown DR; Franco EL; Bernstein DI
    Clin Infect Dis; 2016 Nov; 63(10):1281-1287. PubMed ID: 27655996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
    Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of bivalent HPV vaccination against genital HPV DNA-positivity of a catch-up campaign at age 13-16 years compared to routine vaccination at age 12 years: a biennial repeated cross-sectional study.
    Kusters JMA; van der Loeff MFS; van Benthem BHB; King AJ; ; de Melker HE; Heijman T; Heijne JCM
    BMC Med; 2024 Oct; 22(1):469. PubMed ID: 39407233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of herd effects among women and heterosexual men after girls-only HPV16/18 vaccination in the Netherlands: A repeated cross-sectional study.
    Woestenberg PJ; Bogaards JA; King AJ; Leussink S; van der Sande MA; Hoebe CJ; van Benthem BH;
    Int J Cancer; 2019 Jun; 144(11):2718-2727. PubMed ID: 30426502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey-based cross-sectional analysis.
    Closson K; Karim ME; Sadarangani M; Naus M; Ogilvie GS; Donken R
    Vaccine; 2020 Dec; 38(52):8396-8404. PubMed ID: 33239227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014.
    Han JJ; Beltran TH; Song JW; Klaric J; Choi YS
    JAMA Oncol; 2017 Jun; 3(6):810-816. PubMed ID: 28114440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction.
    Covert C; Ding L; Brown D; Franco EL; Bernstein DI; Kahn JA
    Hum Vaccin Immunother; 2019; 15(7-8):1962-1969. PubMed ID: 30633598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
    Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
    J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018.
    Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
    Ann Intern Med; 2022 Jul; 175(7):918-926. PubMed ID: 35576590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction.
    Widdice LE; Bernstein DI; Franco EL; Ding L; Brown DR; Ermel AC; Higgins L; Kahn JA
    Vaccine; 2019 Oct; 37(45):6832-6841. PubMed ID: 31582269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.